These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 29867235)

  • 41. HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies.
    Bower JF; Li Y; Wyatt R; Ross TM
    Vaccine; 2006 Jun; 24(26):5442-51. PubMed ID: 16621193
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Alterations in the immunogenic properties of soluble trimeric human immunodeficiency virus type 1 envelope proteins induced by deletion or heterologous substitutions of the V1 loop.
    Ching L; Stamatatos L
    J Virol; 2010 Oct; 84(19):9932-46. PubMed ID: 20660181
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.
    Kim M; Qiao ZS; Montefiori DC; Haynes BF; Reinherz EL; Liao HX
    AIDS Res Hum Retroviruses; 2005 Jan; 21(1):58-67. PubMed ID: 15665645
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity.
    Hu JK; Crampton JC; Cupo A; Ketas T; van Gils MJ; Sliepen K; de Taeye SW; Sok D; Ozorowski G; Deresa I; Stanfield R; Ward AB; Burton DR; Klasse PJ; Sanders RW; Moore JP; Crotty S
    J Virol; 2015 Oct; 89(20):10383-98. PubMed ID: 26246566
    [TBL] [Abstract][Full Text] [Related]  

  • 45. N-terminal residues of an HIV-1 gp41 membrane-proximal external region antigen influence broadly neutralizing 2F5-like antibodies.
    Li D; Liu J; Zhang L; Xu T; Chen J; Wang L; Zhao Q
    Virol Sin; 2015 Dec; 30(6):449-56. PubMed ID: 26715302
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Structural and immunologic correlates of chemically stabilized HIV-1 envelope glycoproteins.
    Schiffner T; Pallesen J; Russell RA; Dodd J; de Val N; LaBranche CC; Montefiori D; Tomaras GD; Shen X; Harris SL; Moghaddam AE; Kalyuzhniy O; Sanders RW; McCoy LE; Moore JP; Ward AB; Sattentau QJ
    PLoS Pathog; 2018 May; 14(5):e1006986. PubMed ID: 29746590
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Particulate Array of Well-Ordered HIV Clade C Env Trimers Elicits Neutralizing Antibodies that Display a Unique V2 Cap Approach.
    Martinez-Murillo P; Tran K; Guenaga J; Lindgren G; Àdori M; Feng Y; Phad GE; Vázquez Bernat N; Bale S; Ingale J; Dubrovskaya V; O'Dell S; Pramanik L; Spångberg M; Corcoran M; Loré K; Mascola JR; Wyatt RT; Karlsson Hedestam GB
    Immunity; 2017 May; 46(5):804-817.e7. PubMed ID: 28514687
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Challenges for structure-based HIV vaccine design.
    Schief WR; Ban YE; Stamatatos L
    Curr Opin HIV AIDS; 2009 Sep; 4(5):431-40. PubMed ID: 20048708
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Electron-Microscopy-Based Epitope Mapping Defines Specificities of Polyclonal Antibodies Elicited during HIV-1 BG505 Envelope Trimer Immunization.
    Bianchi M; Turner HL; Nogal B; Cottrell CA; Oyen D; Pauthner M; Bastidas R; Nedellec R; McCoy LE; Wilson IA; Burton DR; Ward AB; Hangartner L
    Immunity; 2018 Aug; 49(2):288-300.e8. PubMed ID: 30097292
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Glycan Hole Area of HIV-1 Envelope Trimers Contributes Prominently to the Induction of Autologous Neutralization.
    Schorcht A; Cottrell CA; Pugach P; Ringe RP; Han AX; Allen JD; van den Kerkhof TLGM; Seabright GE; Schermer EE; Ketas TJ; Burger JA; van Schooten J; LaBranche CC; Ozorowski G; de Val N; Bader DLV; Schuitemaker H; Russell CA; Montefiori DC; van Gils MJ; Crispin M; Klasse PJ; Ward AB; Moore JP; Sanders RW
    J Virol; 2022 Jan; 96(1):e0155221. PubMed ID: 34669426
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Structural Update of Neutralizing Epitopes on the HIV Envelope, a Moving Target.
    Parker Miller E; Finkelstein MT; Erdman MC; Seth PC; Fera D
    Viruses; 2021 Sep; 13(9):. PubMed ID: 34578355
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Live rubella vectors can express native HIV envelope glycoproteins targeted by broadly neutralizing antibodies and prime the immune response to an envelope protein boost.
    Virnik K; Nesti E; Dail C; Scanlan A; Medvedev A; Vassell R; McGuire AT; Stamatatos L; Berkower I
    Vaccine; 2018 Aug; 36(34):5166-5172. PubMed ID: 30037665
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM.
    Antanasijevic A; Sewall LM; Cottrell CA; Carnathan DG; Jimenez LE; Ngo JT; Silverman JB; Groschel B; Georgeson E; Bhiman J; Bastidas R; LaBranche C; Allen JD; Copps J; Perrett HR; Rantalainen K; Cannac F; Yang YR; de la Peña AT; Rocha RF; Berndsen ZT; Baker D; King NP; Sanders RW; Moore JP; Crotty S; Crispin M; Montefiori DC; Burton DR; Schief WR; Silvestri G; Ward AB
    Nat Commun; 2021 Aug; 12(1):4817. PubMed ID: 34376662
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Induction of HIV neutralizing antibodies against the MPER of the HIV envelope protein by HA/gp41 chimeric protein-based DNA and VLP vaccines.
    Ye L; Wen Z; Dong K; Wang X; Bu Z; Zhang H; Compans RW; Yang C
    PLoS One; 2011; 6(5):e14813. PubMed ID: 21625584
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Envelope proteins of two HIV-1 clades induced different epitope-specific antibody response.
    Shrivastava T; Samal S; Tyagi AK; Goswami S; Kumar N; Ozorowski G; Ward AB; Chakrabarti BK
    Vaccine; 2018 Mar; 36(12):1627-1636. PubMed ID: 29429810
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Structural and genetic convergence of HIV-1 neutralizing antibodies in vaccinated non-human primates.
    Cai F; Chen WH; Wu W; Jones JA; Choe M; Gohain N; Shen X; LaBranche C; Eaton A; Sutherland L; Lee EM; Hernandez GE; Wu NR; Scearce R; Seaman MS; Moody MA; Santra S; Wiehe K; Tomaras GD; Wagh K; Korber B; Bonsignori M; Montefiori DC; Haynes BF; de Val N; Joyce MG; Saunders KO
    PLoS Pathog; 2021 Jun; 17(6):e1009624. PubMed ID: 34086838
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neutralizing Antibodies Induced by First-Generation gp41-Stabilized HIV-1 Envelope Trimers and Nanoparticles.
    Kumar S; Lin X; Ngo T; Shapero B; Sou C; Allen JD; Copps J; Zhang L; Ozorowski G; He L; Crispin M; Ward AB; Wilson IA; Zhu J
    mBio; 2021 Jun; 12(3):e0042921. PubMed ID: 34156262
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope.
    Arnold GF; Velasco PK; Holmes AK; Wrin T; Geisler SC; Phung P; Tian Y; Resnick DA; Ma X; Mariano TM; Petropoulos CJ; Taylor JW; Katinger H; Arnold E
    J Virol; 2009 May; 83(10):5087-100. PubMed ID: 19279101
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Development and immunological assessment of VLP-based immunogens exposing the membrane-proximal region of the HIV-1 gp41 protein.
    Benen TD; Tonks P; Kliche A; Kapzan R; Heeney JL; Wagner R
    J Biomed Sci; 2014 Aug; 21(1):79. PubMed ID: 25160824
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.
    Barnett SW; Lu S; Srivastava I; Cherpelis S; Gettie A; Blanchard J; Wang S; Mboudjeka I; Leung L; Lian Y; Fong A; Buckner C; Ly A; Hilt S; Ulmer J; Wild CT; Mascola JR; Stamatatos L
    J Virol; 2001 Jun; 75(12):5526-40. PubMed ID: 11356960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.